Aggressive multiple sclerosis: proposed definition and treatment algorithm
CA Rush, HJ MacLean, MS Freedman - Nature Reviews Neurology, 2015 - nature.com
Multiple sclerosis (MS) is a CNS disorder characterized by inflammation, demyelination and
neurodegeneration, and is the most common cause of acquired nontraumatic neurological …
neurodegeneration, and is the most common cause of acquired nontraumatic neurological …
A review of quantitative risk–benefit methodologies for assessing drug safety and efficacy—report of the ISPOR risk–benefit management working group
JJ Guo, S Pandey, J Doyle, B Bian, Y Lis… - Value in …, 2010 - Wiley Online Library
Objective: Although regulatory authorities evaluate the risks and benefits of any new drug
therapy during the new drug‐approval process, quantitative risk–benefit assessment (RBA) …
therapy during the new drug‐approval process, quantitative risk–benefit assessment (RBA) …
Multiple sclerosis: epidemiologic, clinical, and therapeutic aspects
A Vidal-Jordana, X Montalban - Neuroimaging Clinics, 2017 - neuroimaging.theclinics.com
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system
(CNS) in which inflammation, demyelination, and axonal loss occurs from the very early …
(CNS) in which inflammation, demyelination, and axonal loss occurs from the very early …
Learning from the past and looking to the future: emerging perspectives for improving the treatment of psychiatric disorders
MJ Millan, GM Goodwin, A Meyer-Lindenberg… - European …, 2015 - Elsevier
Modern neuropsychopharmacology commenced in the 1950s with the serendipitous
discovery of first-generation antipsychotics and antidepressants which were therapeutically …
discovery of first-generation antipsychotics and antidepressants which were therapeutically …
Multi-disciplinary fairness considerations in machine learning for clinical trials
While interest in the application of machine learning to improve healthcare has grown
tremendously in recent years, a number of barriers prevent deployment in medical practice …
tremendously in recent years, a number of barriers prevent deployment in medical practice …
Development of a framework for enhancing the transparency, reproducibility and communication of the benefit–risk balance of medicines
PM Coplan, RA Noel, BS Levitan… - Clinical …, 2011 - Wiley Online Library
The current process of benefit–risk assessment of medicines relies primarily on intuitive
expert judgment. Frameworks are needed for transparent, rational and defensible decision …
expert judgment. Frameworks are needed for transparent, rational and defensible decision …
Quantifying benefit–risk preferences for medical interventions: an overview of a growing empirical literature
A Brett Hauber, AO Fairchild… - Applied health economics …, 2013 - Springer
Decisions regarding the development, regulation, sale, and utilization of pharmaceutical and
medical interventions require an evaluation of the balance between benefits and risks. Such …
medical interventions require an evaluation of the balance between benefits and risks. Such …
The risks of risk aversion in drug regulation
HG Eichler, B Bloechl-Daum, D Brasseur… - Nature reviews Drug …, 2013 - nature.com
Drugs are approved by regulatory agencies on the basis of their assessment of whether the
available evidence indicates that the benefits of the drug outweigh its risks. In recent years …
available evidence indicates that the benefits of the drug outweigh its risks. In recent years …
Preference for pharmaceutical formulation and treatment process attributes
KD Stewart, JA Johnston, LS Matza… - Patient preference …, 2016 - Taylor & Francis
Purpose Pharmaceutical formulation and treatment process attributes, such as dose
frequency and route of administration, can have an impact on quality of life, treatment …
frequency and route of administration, can have an impact on quality of life, treatment …
[HTML][HTML] Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: a combined perspective from the MS in the 21st century steering group
P Rieckmann, D Centonze, I Elovaara… - Multiple sclerosis and …, 2018 - Elsevier
Background Patient engagement is vital in multiple sclerosis (MS) in order to optimise
outcomes for patients, society and healthcare systems. It is essential to involve all …
outcomes for patients, society and healthcare systems. It is essential to involve all …